Abstract
AstraZeneca progressed the long acting β2 agonist into Phase II studies for the treatment of asthma and chronic obstructive pulmonary disease in August 2008. These three applications claim specific salt forms of three different long acting β2 agonists, all benzothiazolone derivatives. It would seem that one claims AZD-3199 whereas the other two claim backup compounds.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
